Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Growth 2025-2031
Description
The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (aka DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole cell vaccines, it is considered safer, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity; this is because DTaP"s narrower antigen base is less effective against current pathogen strains.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Forecast” looks at past sales and reviews total world Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales for 2025 through 2031. With Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Immune DTaP Vaccine
Therapy DTaP Vaccine
Segmentation by Application:
Adult
Pediatric
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market?
What factors are driving Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market opportunities vary by end market size?
How does Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (aka DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole cell vaccines, it is considered safer, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity; this is because DTaP"s narrower antigen base is less effective against current pathogen strains.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Forecast” looks at past sales and reviews total world Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales for 2025 through 2031. With Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Immune DTaP Vaccine
Therapy DTaP Vaccine
Segmentation by Application:
Adult
Pediatric
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market?
What factors are driving Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market opportunities vary by end market size?
How does Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
120 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
